The 5 mg risdiplam tablet provides the same efficacy and safety for spinal muscular atrophy as the currently available oral ...

GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN –– Approval based on positive data ...

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

The right drawing tablet can make all the difference in bringing your creative vision to life. It should feel like an extension of your hand, translating every brushstroke with precision and fluidity.

A Prescription Drug User Fee Act target date of September 14, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application ...

Is the MG4 a good car? Small electric cars have historically been expensive, but the MG4 marked the beginning of price parity with more traditionally powered hatchbacks. But it isn't just the ...

The reMarkable 2 e-ink tablet is an impressive piece of tech that managed to significantly slim down the original version of the doodler's notepad replacement. Rather than acting like a big ...

offering a fresh take on how tablets can fit into everyday life. Meanwhile, OnePlus has entered the fray with the OnePlus Pad 2, a value-packed device featuring top-tier hardware that clearly takes ...

If she goes, she risks not coming back to her family or her beloved island. Here's where Moana 2 really shows us how far Moana has grown. With age and greater status in Motunui, she's become far ...

We're not done with tablets, and we have some great devices in Future Labs and the hands of our reviewers. We'll have a full review of the OnePlus Pad 2 soon, a sequel to one of our favorite ...

Bumetanide Nasal Spray (RSQ-777) is being developed as a convenient, outpatient-focused therapy for edema associated with congestive heart failure, as well as liver and kidney disease. “We are pleased ...

for its novel Bumetanide Nasal Spray (RSQ-777). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 14, 2025.